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Summary The clinical use of anti-oestrogens in breast cancer therapy has traditionally been restricted to
tumours that contain measurable oestrogen receptor protein. However, it is now widely recognised that the
clinical response to adjuvant anti-oestrogen therapy appears to be independent of the oestrogen receptor
content of the primary tumour. The study reported here was designed to investigate the possibility that human
stromal cells can respond to anti-oestrogens by an increased synthesis of the inhibitory growth factor,
transforming growth factor beta (TGF-beta). Two established human fetal fibroblast strains were used as
models for the breast cancer stromal fibroblasts. These cells were found to respond to the addition of
anti-oestrogens by a large increase in their synthesis of biologically active TGF-beta. Despite the application of
ligand binding, immunoassay and Northern analysis, no oestrogen receptor or oestrogen receptor mRNA was
detected in either of the human fetal fibroblasts strains. These observations may provide a mechanism of
action of anti-oestrogens that is independent of the presence of oestrogen receptor in the tumour epithelial
cells, and thus provide an explanation for the counter-intuitive results of adjuvant anti-oestrogen action.
Anti-oestrogens are important agents for the treatment of
breast cancer. They have recently been shown to induce the
secretion of transforming growth factor-beta (TGF-beta), a
potent inhibitor of epithelial cell growth, from MCF-7 breast
cancer cells in vitro, through an oestrogen receptor-dependent
mechanism (Knabbe et al., 1987). However, clinical trials
designed to investigate the therapeutic efficacy of adjuvant
anti-oestrogens in the treatment of breast cancer have yielded
paradoxical results in that response appears to be indepen-
dent of the oestrogen receptor (ER) status of the primary
tumour (Nolvadex Adjuvant Trial Organisation, 1987;
Medical Research Council Scottish Trials Office, 1988), and
the recent overview of all the adjuvant trials to date shows
that ER status fails to predict any group of patients that do
not respond to anti-oestrogen treatment (Early Breast Cancer
Triallists Collaborative Group, 1988). These unexpected
findings led us to investigate the hypothesis that anti-
oestrogens might induce the secretion of TGF-beta from
stromal cells, which comprise a large proportion of the cell
types present in most tumours, via a novel biological
mechanism. Here we show that anti-oestrogens induce a 3 to
30-fold increase in secreted TGF-beta from two different
human fetal fibroblast strains, despite a demonstrated lack of
ER within these cells. In contrast to other cellular systems,
less than 30% of the secreted TGF-beta is in the biologically
latent form.
The consensus from in vitro studies is that oestrogen
antagonists act upon ER + ve breast cancer cells to block the
mitogenic effect of oestradiol, but that ER-ve cells are
unaffected (Korenman & Dukes, 1970; Skidmore et al.,
1972). Similarly, anti-oestrogens induce the secretion of
TGF-beta, a potent epithelial inhibitor which may contribute
to the antimitogenic action of anti-oestrogens, from ER + ve
but not from ER-ve breast cancer cell lines (Knabbe et al.,
1987). Thus, we reasoned that some other cells in the tumour
might be responsible for mediating the in vivo response of
ER-ve tumours to anti-oestrogens such as tamoxifen. An
influence of stromal fibroblasts on the growth of malignant
breast-derived epithelial cells has been demonstrated both in
vivo and in vitro (Gleiber & Schiffman, 1984; Horgan et al.,
1987). Recent data have also shown that fibroblasts isolated
from hereditary breast cancer patients display fetal character-
istics in culture (Haggie et al., 1987). These observations led
us to use two human fetal fibroblast strains, from the lung
(Flow 2002) and the pituitary (Flow 9000), as experimental
models for the breast tumour stromal fibroblasts, to deter-
mine whether anti-oestrogens might induce production of an
inhibitor of epithelial growth such as TGF-beta from these
cells.
Materials and methods
Cell culture andpreparation ofconditioned media Flow 2002
fetal lung fibroblasts and Flow 9000 fetal pituitary fibroblasts
(early passage, obtained from Flow Laboratories UK Ltd.,)
were seeded at a density of 2 x 106 cells per 175 cm2 flask in
phenol red-free Modified Eagles Medium (MEM) sup-
plemented with 2 mM L-glutamine and 10% dialysed fetal calf
serum (dFCS), treated with dextran-coated charcoal (Green
& Leake, 1987). These cells were allowed to grow for 3 days,
until approximately 50% confluent. The medium was then
discarded and the cell monolayers washed twice with warm
phosphate-buffered saline. The cells were then incubated with
50 ml of a defined medium consisting of phenol red-free
MEM, supplemented with 2 mM L-glutamine, MEM
vitamins, 5 yg ml-1 bovine insulin, 5 jig ml' human transfer-
rin, 2 lag ml-' bovine fibronectin, 10 ng ml-' bovine epider-
mal growth factor, 1 nM sodium selenite and 0.5 nM cupric
sulphate. After 24 h this medium was discarded and replaced
with a fresh 50 ml of the same medium containing the test
compounds in ethanol (final ethanol concentration 0.1% v/
v). Oestradiol and dihydrotestosterone were used at 10 nM
and all other agents at 500 nM. Control cells received only
the ethanol vehicle. After 48 h the conditioned media were
collected into siliconised glass bottles, clarified by ultracen-
trifugation at 105,000 g for 30 min at 4'C followed by
lyophilisation. The cell monolayers were trypsinised and the
cells counted. Under all the experimental conditions the cell
viability was greater than 95% as assessed by trypan blue dye
exclusion. The lyophilisates were then reconstituted with
15 ml of water containing 10 tgml-' leupeptin, Ofig ml-'
aprotinin and 50tcg ml-I bovine serum albumin. These were
then extensively dialysed (6 changes over 72 h at 4C) against
50 mM ammonium acetate and the dialysed conditioned
media relyophilised. The resulting material was then ex-
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tracted twice with 1 ml aliquots of 4 mM HC1. These extracts
were used for subsequent assays. This dialysis and acid ex-
traction procedure was critical to remove components that
interfered with the radioreceptor assay.
Radioreceptor assays for TGF-beta TGF-beta in the 4 mM
HCl extracts was measured in a radioreceptor assay using a
two-step format in which the sample and the iodinated TGF-
beta are bound sequentially to prevent interference by TGF-
beta binding proteins, as fully described previously
(Wakefield et al., 1987). The results are the mean ± S.D. of 3
(control, oestradiol, dihydrotesterone, dexamethasone and
the progestogens) or 6 (tamoxifen, toremifene) determina-
tions from a representative experiment. [MPA, medroxypro-
gesterone acetate; R5020, promegestone; gestodene, 17-alpha-
ethinyl-13-beta-ethyl-17-beta-hydroxy-4, 15-oestradiene-3-
one.] For further analyses, serum-free conditioned media
were collected from drug-treated cells and, after removal of
2 ml aliquots for assay of the fraction of secreted TGF-beta
in the latent form (Wakefield et al., 1987), were dialysed and
acid-extracted as described above. The anti-oestrogens
tamoxifen, 4-hydroxy-tamoxifen and N-n-butyl-l 1- (3, 17-
beta-dihydroxyoestra-1,3,5 (10)-trien-7-alpha-yl)-N-methly-
undecanamide (ICI 164,384) were used at final concentra-
tions of 500 nM and for competition studies oestradiol was
used at 100 nM. The control received ethanol vehicle (0.1% v/
v) alone. The fraction of TGF-beta secreted in the
biologically latent form was determined by comparing
receptor-reactive TGF-beta in unextracted conditioned media
samples before and after activation of the latent species by
transient acidification to pH 2-3 (Wakefield et al., 1987).
Receptor binding activity due to authentic TGF-beta was
verified by reversal of the receptor binding with specific
anti-TGF-beta 1 antibodies, since the undialysed, unextracted
conditioned media contained components that interfered with
this assay, resulting in bizarre, non-parallel competition
curves. The fraction of latent TGF-beta in the samples
treated with both tamoxifen and oestradiol could not be
determined due to the presence of strongly interfering com-
ponents in these unextracted conditioned media, and the
latent fraction in control samples could not be determined
because the amounts of TGF-beta involved were too small.
Oestrogen receptor assays Whole cell extracts were prepared
from both the Flow 2002 and 9000 cells by sonicating 5 x 10'
cells in 10 mM Tris-HCI pH 7.4, containing 1.5 mM EDTA,
1 mM dithiothreitol and 500 mM KCI at 2°C. The sonicates
were then centrifuged at 105,000g for 30 min. Aliquots of
the supernatants were then incubated with a constant amount
(0.03pCi) of 3H-oestradiol and increasing amounts of
radioinert oestradiol (0-20 pmol). After a 4 h incubation at
4°C, receptor and specifically bound ligand were immobilised
by affinity chromatography on Cibacron Blue F3GA-
Sepharose 6B as previously described (Iqbal et al., 1985). The
immunoassay of oestrogen receptor was performed with the
Abbott Laboratories ER-EIA kit exactly according to the
protocol supplied by the manufacturer.
Immunoprecipitation ofmetabolically-labelled TGF-beta I and
TGF-beta 2 from the conditioned medium of Flow 9000
cells Cells were seeded (5 x 105) into 25 cm2 flasks in MEM
containing 5% dFCS and grown for 48 h. The medium was
then replaced with cysteine- and methionine-free MEM con-
taining 5% dFCS and 25% of the normal concentration of
both cysteine and methionine. To these were added 10 nm
oestradiol, 500 nM tamoxifen, 500 nM toremifene or the
ethanol vehicle alone (0.1% v/v). After 12 h with the drugs
the cells were pulsed for 20 h with 35S-cysteine
(0.125 mCi ml-'), and the labelled conditioned media were
transferred to siliconised tubes and clarified. Aliquots of the
clarified supernatents, containing 106 trichloroacetic acid-
precipitable counts, were then lyophilised after the addition
of 10jgml-' phenylmethylsulphonyl fluoride and leupeptin.
The lyophilised material was then redissolved in 1 ml of IP
buffer (50 mM Tris-HCI pH 7.5, containing 0.15 M NaCl,
1 mM EDTA, 1% Triton-X 100, 1% sodium deoxycholate,
0.1% SDS and 0.005% thiomersal) and preadsorbed with
100 tg ml-' normal rabbit IgG. Samples were then
immunoprecipitated with an ammonium sulphate-purified
anti-TGF-beta 2 rabbit antibody (S3/28) in duplicate sam-
ples, using antibody alone or antibody preincubated for 12 h
with 250 ng ml-' TGF-beta 2. After precipitation of
immunoreactive material with Staph. aureus, the supernatants
were reincubated with affinity purified rabbit anti-TGF-beta
1 antibody (LC14) either alone, or with antibody prein-
cubated with 250 ng TGF-beta 1, and precipitated as above.
The resulting pellets were then washed four times with IP
buffer and resorbed on a 10% non-reducing SDS polyac-
rylamide gel according to the method of Laemmli (1970).
Authentic '251-TGF-beta was run as a marker.
Bioassay of the secreted TGF-beta Conditioned media from
steroid or antagonist treated Flow 9000 cells were collected,
dialysed, concentrated and acid-extracted as described above.
Extracts were tested for the ability to inhibit the incorpora-
tion of '251I-deoxyuridine in monolayer cultures of CCL64
mink lung cells as previously described (Danielpour et al.,
1989). Incorporation is expressed as a percent of the control
value (1117±65c.p.m. n=4) obtained in the presence of
added PBS/0.1% BSA, which was the carrier for all samples,
and corrected for the incorporation (137 ± 15 c.p.m. n = 4)
obtained at maximal inhibition in the presence of 10 pM
TGF-beta. Since all the 4 mM HCI extracts contained
additonal mitogenic and growth inhibitory components, the
contribution due to TGF-beta was demonstrated using type-
specific polyclonal turkey (anti-TGF-beta 1: T366) or rabbit
(anti-TGF-beta 2: V6/30) immunoglobulin preparations
specifically to reverse any growth inhibition due to TGF-
beta.
Northern analysis Total cellular RNA from cells treated
with ethanol vehicle and cells treated with either 500 nM
tamoxifen, 500 nM tamoxifen plus 100 nM oestradiol, 500 nM
4-hydroxytamoxifen or 500 nM ICI 164,384 was prepared by
the guanidium isothiocyanate/CsCl gradient method
(Maniatis et al., 1983). 10,lg samples of these were resolved
on a 1% agarose gel containing formaldehyde and transfer-
red to GeneScreen. Following overnight prehybridisation in
0.05 M Tris-HCI (pH 7.5) containing 50% formamide, 0.2%
polyvinylpyrrolidone, 0.2% BSA, 0.2% ficoll, 1 M NaCI,
0.1% sodium pyrophosphate, 1% SDS, 10% dextran sul-
phate and 100pgml-' sonicated salmon sperm DNA, the
filter was hybridised to a random primer labelled (Feinberg &
Vogelstein, 1983) SacI/PvuII fragnent derived from the
entire porcine TGF-beta 1 cDNA (Kondaiah et al., 1988).
The filter was washed twice in 2 x SSC (SSC is 0.15 M NaCl,
0.015 M sodium citrate) at 20°C for S min, once in 1 x SSC
with 0.1% SDS at 20°C for 15 min and once in 0.5 x SSC
with 0.1% SDS at 55°C for 30 min followed by exposure to
X-ray film at - 70°C for 72 h.
Results
Treatment of both these fibroblast strains with subtoxic con-
centrations of the anti-oestrogen tamoxifen, or its chlorinated
derivative, toremifene, resulted in a significant induction of
receptor-reactive TGF-beta (Table I). Little or no induction
was observed with oestradiol, three progestogens (MPA,
R5020 and gestodene), dihydrotestosterone or dex-
amethasone. Flow 9000 cells showed a 27-fold induction of
TGF-beta in response to tamoxifen, with toremifene being
approximately half as effective. The induction observed in
Flow 2002 cells in response to tamoxifen was approximately
5-fold over control levels, indicating that the inductive res-
ponse was not restricted to a single cell strain.
Using a sensitive ligand binding technique and an
immunoassay technique, the two fibroblast strains were
examined for the presence of the ER protein, with the
ER + ve breast cancer line MCF-7 used as a positive control.ANTI-OESTROGENS AND HUMAN FIBROBLASTS 407
No ER was detectable in the fibroblasts using either of these
methods. Figure 1 illustrates that both fibroblast strains were
devoid of any measurable ER by ligand binding using the
affinity chromatography technique (detection limit 0.2 fmol
of receptor per mg of soluble cellular protein), while the
MCF-7 cells showed the expected high affinity intracellular
receptor. Similarly, both of the fibroblast strains also failed
to show any immunoreactive ER when assayed with an
immunoassay kit from Abbott Laboratories, (detection limit
1.5 fmol of receptor per mg of soluble cellular protein, data
not shown). Northern analysis of poly-A+ selected mRNA
from both of the fibroblast strains also failed to show any
ER mRNA although a positive signal was obtained for
poly-A + mRNA prepared from MCF-7 cells (data not
shown). These observations suggest that the induction of
TGF-beta might be mediated by a novel mechanism that
does not involve the conventional ER. Further evidence in
support of this is provided by the data in Table II. Oest-
radiol, used at a concentration (100nM) that should fully
abolish the binding of 500nM tamoxifen to any ER that
might be present, due to the much lower relative binding
affinity of the antagonist for ER (Sutherland, 1981) causes
less than a 50% reduction in the amount of TGF-beta
secreted in response to tamoxifen. The reduction in TGF-
beta secretion that is observed is probably due to a non-
specific metabolic effect caused by the use of such a sup-
raphysiological oestradiol concentration. By contrast, the
induction of TGF-beta by anti-oestrogens in MCF-7 cells
was fully reversible by oestradiol, consistent with an ER-
mediated induction. Interestingly, in the present work, the
putative active metabolite of tamoxifen, 4-hydroxy-tamoxifen
(Jordan et al., 1977), was no more potent than the parent
compound in inducing TGF-beta (Table II). ICI 164,384,
which is a pure oestrogen antagonist devoid of any agonist
activity (Wakeling & Bowler, 1987), although less effective
than tamoxifen, also caused a significant induction (Table II).
Most cells in 'culture secrete TGF-beta in a biologically latent
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Figure 1 Scatchard analysis of oestrogen receptor in MCF-7,
Flow 2002 and Flow 9000 cells by affinity immobilisation on
Cibacron Blue F3GA-Sepharose 6B.
Table I Total TGF-beta secretion rates for the Flow 2002and Flow9000cells. Secretion
rates are presented as ng per 106 producercells per48 h inmonolayerculture, and are the
means ± thestandarddeviationsoftriplicateestimations fromduplicateexperiments. The
relative inductions are normalised to the ethanol vehicle control which were set at 1.0.
FLOW 2002 FLOW 9000
TGF-beta (ng 10-6 TGF-beta (ng 10-6
x cells 48 h') Rel. InJa .x cells 48 h-') Rel. In.0
Control 0.4 ± 0.1 1.0 0.6 ± 0.0 1.0
10 nM Oestradiol 0.3 0.1 0.8 1.2 0.2 1.9
500 nm Tamoxifen 2.0 ± 0.5 5.0 16.7 ± 5.3 27.4
500 nM Toremifene 1.1 0.2 2.7 6.8 3.6 11.2
500nM MPA <0.3 <0.8 <0.4 <0.8
500 nm R5020 <0.3 <0.8 <0.4 <0.8
500 nM Gestodene <0.3 <0.8 <0.4 <0.8
10nM DHT 0.5±0.1 1.3 0.5±0.0 1.0
500 nM Dexamethasone <0.3 <0.8 0.5 ± 0.0 0.9
'Rel. In. = relative induction.
Table II Total TGF-beta secretion rates for Flow9000cellsand thepercentage ofthisas
the active peptide. Secretion rates are presented in ngper I06producer Flow9000cellsper
48 h in monolayer culture, and are the means ± the standard deviations of triplicate
estimations of two separate experiments. The relative inductions are normalised to the
ethanol vehicle control which was set at 1.0
TGF-beta secreted Active TGF-beta
ng 10-6 x cells 48 h- Rel. In.a (% oftotal)
Control 0.8 ± 0.3 1.0 N.D.
0.9±0.3 1.1
500 nM Tamoxifen 20.7 1.8 25.9 70
27.9 ± 2.9 34.9
500 nM Tamoxifen + 11.8 ± 0.9 14.8 N.D.
100 nM Oestradiol 10.8 ± 0.9 13.5
500nM 4-Hydroxy- 17.3 1.0 21.6 72
tamoxifen 19.7 3.0 24.6
500nM ICI 164,384 8.8±0.7 11.0 100
9.0± 1.1 11.3
aRel. In. = relative induction.408 A.A. COLLETTA et al.
form that is unable to bind to the cellular TGF-beta receptor
(Pircher et al., 1984; Lawrence et al., 1984; Wakefield et al.,
1987). By contrast, the TGF-beta secreted by the fetal fibrob-
lasts in response to the anti-oestrogens was 70-100% in the
receptor-reactive form (Table II). To date, only two other cell
systems have been shown to secrete a substantial amount of
active rather than latent TGF-beta. These are MCF-7 cells
treated with tamoxifen (Knabbe et al., 1987) and primary
cultures of mouse keratinocytes treated with retinoic acid
(Glick et al., 1989).
To demonstrate that the TGF-beta recovered in the condi-
tioned media was synthesised by the fibroblasts, rather than
representing TGF-beta sequestered from culture components
such as serum or fibronectin and later released, cells were
metabolically labelled and the media immunoprecipitated
with antibodies specific for two of the known TGF-beta
subtypes. The data in Figure 2 confirm that the anti-
oestrogens induce de novo synthesis of TGF-beta. Further-
more, they show the induction is specific for TGF-beta 1, or
an immunologically related species, since there is no apparent
induction of TGF-beta 2. In addition, extracts of the condi-
tioned media from treated cells inhibited the growth of
CCL64 cells, and this growth inhibition could be reversed by
the addition of specific anti-TGF-beta 1 but not anti-TGF
beta 2 antibodies (Figure 3). A complex mixture of mitogens
and other inhibitors appeared to be present in all the extracts
tested, but only conditioned media from those cells treated
with anti-oestrogens showed inhibition that was specifically
reversible with anti-TGF-beta antibodies. This demonstrates
that the TGF-beta secreted has biological activity, and con-
firms that it is TGF-beta 1, or a very closely related species,
and not TGF-beta 2. Two other TGF-beta subtypes (TGF-
beta 3 and TGF-beta 4) have recently been described (Ten
Dijke et al., 1988; Jakowlew et al., 1988). While our TGF-
beta 1 antibodies show less than 1% cross-reactivity with
TGF-beta 2 and TGF-beta 3 (our unpublished data), the
extent of cross-reactivity with TGF-beta 4 cannot be deter-
mined until the corresponding protein becomes available.
However, since the cDNA for TGF-beta 4 encodes a protein
with no signal peptide, it is highly unlikely that the secreted
peptide we observed is TGF-beta 4 rather than TGF-beta 1.
Northern analysis showed no significant increase in TGF-
beta I mRNA in cells treated with tamoxifen, 4-
hydroxytamoxifen or ICI 164,384 compared with control
cells (Figure 4). Indeed, a slight decrease in message levels
was observed with ICI 164,384. Thus the mechanism of
TGF-beta 1 induction by anti-oestrogens in these cells
appears to be post-transcriptional. The induction of TGF-
beta by anti-oestrogens in MCF-7 cells was also suggested to
be post-transcriptional, although in that system induction
appeared to be mediated by the classical ER (Knabbe et al.,
1987) so the detailed mechanisms must differ between the two
systems.
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Figure 2 Immunoprecipitation of metabolically labelled TGF-
beta 1 and TGF-beta 2 in the conditioned media from Flow 9000
cells. Drug treatments are indicated above the figure panels. The
antibody specificity was tested by preincubation with 250 ng of
either TGF-beta 1 or TGF-beta 2 as a blocking peptide. Drug
concentrations are described in Materials and methods.
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Figure 3 CCL64 bioassay for TGF-beta with antibody reversal
in a 1:250 dilution of the Flow 9000 conditioned media. Full
details are provided in Materials and methods.
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Figure 4 Northern analysis of total cellular RNA from drug-
treated Flow 9000 cells, hybridised to a specific insert derived
from the TGF-beta 1 cDNA.
Discussion
We have demonstrated for the first time an unequivocal
biological action of anti-oestrogens despite the apparent lack
of classical ER. The fetal fibroblasts used were devoid of this
receptor by four distinct criteria-:. absence of functional
protein in a sensitive ligand binding assay; absence of
immunoreactive protein; lack of complete reversibility of the
anti-oestrogen effect by high concentrations of oestradiol;
and lack of any specific mRNA for ER. However, we cannot
totally exclude the possibility that there exist in these cells a
very small number of ER molecules that are beyond the
detection limits of the methods used in our experiments.
Since the oestrogen antagonist ICI 164,384 induces TGF-
beta, but does not have the structural requirements for bind-
ing to the anti-oestrogen binding site characterised by Watts
et al. (1984), the mechanism of TGF-beta induction by anti-
oestrogens does not appear to involve these sites. We
anticipate that a novel binding site may be involved,
although the structural dissimilarity of tamoxifen and ICI
164,384 suggest that these two drugs are unlikely to act via a
common receptor, unless it were closely related to the con-
ventional ER. This might be one of the many so-called
'orphan receptor' cDNAs that have recently been identified
on the basis of their extensive sequence homology to the
human ER (Giguere et al., 1988; Murphy & Dotzlaw, 1989).
The demonstration that pharmacological agents such as anti-
oestrogens can induce the synthesis of an epithelial growth
inhibitor by stromal cells opens a new horizon in the therapy
and prevention of epithelial cancers.ANTI-OESTROGENS AND HUMAN FIBROBLASTS 409
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